Tumour eradication with high-dose idarubicin-anti-Ly-2.1 with murine tumour necrosis factor-α in mice

Immunology and Cell Biology

Volumn 75, Issue 3, 1997, Pages 253-258

  Pietersz, Geoffrey A ^a   Bogdanovski, Mary ^a   Wenjun, Li ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

Idarubicin; Immunoconjugate; Metastases; Monoclonal antibody; Synergy; Thymoma; Tumour necrosis factor

Indexed keywords

ANTIBODY CONJUGATE; IDARUBICIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LY 2 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG POTENTIATION; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; THYMOMA; TUMOR CELL DESTRUCTION; TUMOR IMMUNOLOGY;

ANIMALIA; MURINAE;

EID: 0030751555     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1038/icb.1997.39     Document Type: Article

References (38)

1. Pietersz GA, Smyth MJ, McKenzie IFC. The use of anthracycline antibody complexes for specific anti-tumor therapy. Targeted Diagn. Ther. 1988; 1: 25-53.
2. Rowland AJ, McKenzie IFC, Pietersz GA. Preclinical investigation of the antitumour effects of anti-CD-19-idarubicin immunoconjugates. Cancer Immunol. Immunother. 1993; 37: 195-202.
3. Pietersz GA, McKenzie IFC. Antibody conjugates for the treatment of cancer. Immunol. Rev. 1992; 129: 57-80.
4. Smyth MJ, Pietersz GA, McKenzie IFC. Selective enhancement of antitumor activity of N-acetyl melphalan on conjugation to monoclonal antibodies. Cancer Res. 1987; 47: 62-9.
5. Smyth MJ, Bogdanovski M, McKenzie IFC, Pietersz GA. The antitumour activity of idarubicin-monoclonal antibody conjugates in a disseminated thymoma model. Cancer Res. 1991; 51: 310-17.
6. Noguchi A, Takahashi T, Yamaguchi T et al. Preparation and properties of the immunoconjugate composed of anti-human colon cancer monoclonal antibody and mitomycin C-dextran conjugate. Bioconj. Chem. 1992; 3: 132-7.
7. Smyth MJ, Foster H McA, Andrew SM et al. Immunochemotherapy of human colon carcinoma xenografts in nude mice using combinations of idarubicin monoclonal antibody conjugates. Immunol. Cell Biol. 1993; 71: 167-79.
8. 2 conjugates. Br. J. Cancer 1987; 55: 7-11.
9. Chari RVJ, Martell BA, Gross JL, Shah SA, Blatter WA, McKenzie IFC. Immunoconjugates containing novel maytansinoids: Promising anticancer drugs. Cancer Res. 1992; 52: 127-31.
10. Smyth MJ, Pietersz GA, McKenzie IFC. Use of vasoactive agents to increase tumor perfusion and the antitumor efficacy of drug-monoclonal antibody conjugates. J. Natl Cancer Inst. 1987; 79: 1367-73.
11. Pietersz GA, Krauer K. Antibody-targeted drugs for the therapy of cancer. J. Drug Targeting 1994; 2: 183-215.
12. Aggarwal BB, Hass PE, Kohr WJ et al. Human tumour necrosis factor alpha and beta: their biochemical and biological properties. In: Ishigami S (ed.) Recent advances in chemotherapy. Proceedings of the 14th International Congress of Chemotherapy; 1985; Kyoto. Tokyo: University of Tokyo Press, 1985; 83-5.
13. Shalaby MR, Aggarwal BB, Rinderknecht E, Sverdersky LP, Finkle BS, Palladino MA. Activation of human polymorphonuclear neutrophil functions by interferon-γ and tumor necrosis factors. J. Immunol. 1985; 135: 2069-73.
14. Bemelmans MHA, van Tits LJH, Buurman WA. Tumor necrosis factor: Function, release and clearance. Crit. Rev. Immunol. 1996; 16: 1-11.
15. Fransen L, Van Der Heyden J, Ruysschaert R, Fiers W. Recombinant tumor necrosis factor: its effect and its synergism with interferon-γ on a wide variety of normal and transformed human cell lines. Eur. J. Cancer Clin. Oncol. 1986; 22: 419-26.
16. Lee SH, Aggarwal BB, Rinderknecht E, Assisi F, Chiu H. The synergistic anti-proliferative effect of γ-interferon and human lymphotoxin. J. Immunol. 1984; 133: 1083-6.
17. Khan A, Pichyangkul S. Potentiation of in vitro antitumor effect of lymphotoxin by antitumor drugs and elevated temperature. Proc. Am. Assoc. Cancer Res. 1985; 26: 304.
18. Spofford BT, Daynes RA, Granger GA. Cell-mediated immunity in vitro: a highly sensitive assay for human lymphotoxin. J. Immunol. 1974; 112: 2111-16.
19. Lienard D, Lejeune F, Delmotte J, Renard N, Ewalenco P. High-dose recombinant tumor necrosis factor-α in combination with interferon-γ and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 1992; 10: 52-60.
20. Regenass U, Muller M, Curschellas E, Matter A. Anti-tumor effects of tumor necrosis factor in combination with chemotherapeutic agents. Int. J. Cancer 1987; 39: 266-73.
21. Fiers W, Brouckaert AL, Goldberg AL et al. Structure-function relationship of tumour necrosis factor and its mechanism of action. In: Tumour necrosis factor and related cytotoxins. Ciba Foundation Symposium 131; 1987; London. Chichester: John Wiley & Sons Ltd, 1987; 109-23.
22. McIntosh JK, Mule JJ, Krosnick KA, Rosenberg SA. Combination cytokine immunotherapy with tumour necrosis factor α, interleukin 2, and α-interferon, and its synergistic antitumor effects in mice. Cancer Res. 1989; 49: 1408-14.
23. Nishimura T, Ohta S, Sato N, Togashi Y, Goto M, Hashimoto Y. Combination tumour-immunotherapy with recombinant tumour necrosis factor and recombinant interleukin 2 in mice. Int. J. Cancer 1987; 40: 255-61.
24. Williamson BD, Carswell EA, Rubin BY, Prendergast JS, Old LJ. Human tumour necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc. Natl Acad. Sci. USA 1983; 80: 5397-401.
25. Kettlehut IC, Fiers W, Goldberg AL. The toxic effects of tumour necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Proc. Natl Acad. Sci. USA 1987; 84: 4273-7.
26. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumours. Proc. Natl Acad. Sci. USA 1975; 72: 3666-70.
27. Ii ES, Ulich TR. Endotoxin, interleukin-1 and tumor necrosis factor cause neutrophil-dependent microvascular leakage in postcapillary venules. Am. J. Pathol. 1992; 140: 659-63.
28. Smyth MJ, Pietersz GA, McKenzie IFC. Increased antitumour effect of immunoconjugates and tumor necrosis factor in vivo. Cancer Res. 1988; 48: 3607-12.
29. Russell S, McKenzie IFC, Krauer K, Pietersz GA. Effect of tumor necrosis factor on the antitumor efficacy and toxicity of aminopterin-monoclonal antibody conjugates: parameters in optimization of therapy. Cancer Res. 1990; 50: 6028-33.
30. Hogarth PM, Edwards J, McKenzie IFC, Goding JW, Liew FY. Monoclonal antibodies to murine Ly-2.1 cell surface antigen. Immunology 1982; 46: 135-44.
31. Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A Sepharose. Immunochemistry 1978; 15: 429-34.
32. Pietersz GA, Smyth MJ, McKenzie IFC. Immunochemotherapy of a murine thymoma with idarubicin-monoclonal antibody conjugates. Cancer Res. 1988; 48: 926-31.
33. Smyth MJ, Pietersz GA, Classon BJ, McKenzie IFC. The specific targeting of chlorambucil to tumours. J. Natl Cancer Inst. 1986; 76: 503-10.
34. Berenbaum MC. Synergy, additivism and antagonism in immunosuppression. Clin. Exp. Immunol. 1977; 28: 1-18.
35. Fiers W. Tumor necrosis factor: Characterization at the molecular, cellular and in vivo level. FEBS Lett. 1991; 285: 199-212.
36. Semenzato G. Tumour necrosis factor: a cytokine with multiple biological activities. Br. J. Cancer 1990; 61: 354-61.
37. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N. Engl. J. Med. 1987; 316: 379-85.
38. Dealtry GB, Naylor MS, Fiers W, Balkwill FR. DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon-gamma. Eur. J. Immunol. 1987; 17: 689-93.